AbbVie and Alphabet company commit $1bn to collaboration
AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.
23 April 2026 Plaintiff alleges that a $6 billion rival probed its records system via a long-term customer, using confidential information to develop its product in the behavioural health tech space.
